Darden’s Analyst Adjustments and 4 Stock Analyses Turning Heads

After Royalty Pharma offered to buy Elan Corp. PLC. for $11 per share, RBC Capital believes that they may raise their offer to $12 per share, but the firm expects Elan to reject this offer as well. RBC believes that Elan will follow their stated strategy and maintain a Sector Perform rating on the shares.